🇺🇸 cis-platinum in United States

44 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Inappropriate Antidiuretic Hormone Secretion — 9 reports (20.45%)
  2. Pyrexia — 6 reports (13.64%)
  3. Asthenia — 5 reports (11.36%)
  4. Bone Marrow Failure — 5 reports (11.36%)
  5. Gastrointestinal Disorder — 4 reports (9.09%)
  6. Decreased Appetite — 3 reports (6.82%)
  7. Drug Ineffective — 3 reports (6.82%)
  8. Drug Resistance — 3 reports (6.82%)
  9. Haematochezia — 3 reports (6.82%)
  10. Neuropathy Peripheral — 3 reports (6.82%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is cis-platinum approved in United States?

cis-platinum does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for cis-platinum in United States?

Peking University Third Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.